Print this issue
Send your comments

James K. Laird, CEO of BioPortUSA, announced today the launch of a commercialization accelerator that targets foreign life sciences companies wishing to establish a business presence in the U.S. market. BioPortUSA offers these companies access to U.S. market industry experts that first, undertake a comprehensive assessment of their readiness to enter the U.S. market; second, develop a highly customized commercialization plan; and third, implement some or all of the plan recommendations to assure efficient and effective market entry.

"BioPortUSA simplifies the U.S. market entry process and helps foreign companies navigate the changing FDA regulatory environment, as well as the legal, tax, immigration and commercialization requirements that they will face in establishing a U.S. business presence. By engaging BioPortUSA, client companies access a menu of core professional services all in one place that will enable them to correctly determine their early investment and accelerate the commercialization process for their product lines," said BioPortUSA CEO James K. Laird.

In partnership with an elite group of U.S. based professional service firms all with international reach, BioPortUSA is able to aggregate all the service requirements of life sciences firms entering the U.S. market. Current BioPortUSA partners include: Amper, Politziner & Mattia (accounting, tax & audit); Ashton Tweed (executive recruiting and commercialization management consulting); Morgan, Lewis & Bockius (legal); PharmaNet Development Group (clinical drug development and regulatory consulting services); and Wachovia Insurance Services (insurance broker). All of these partner companies are represented at the BIO 2007 International Convention and are here supporting their participation in BioPortUSA.

BioPortUSA services are well-suited for funded life sciences firms with therapeutics (drug compounds or biologics), medical devices, diagnostics, or platform technologies well advanced in their clinical programs or launched in their respective domestic market. By outsourcing commercialization services to professionals who are experienced in and knowledgeable of the U.S. market, companies can operate as a virtual company for a longer period of time thereby reducing operational costs and accelerating the time-to-market process.

James K. Laird, CEO of BioPortUSA, will be moderating the Coming to America: Establishing a Business Presence in the United States panel on Wednesday, May 9, 2007 at 11:00 AM in room 254 AB at the BIO International Convention in Boston. Speakers at the session include: Manya Deehr, JD, Chief Legal Officer, Eurand, Inc.; Giorgio Mosconi, MD, PhD, Chief Scientific Officer, Acureon Pharma; William Ashton, MA, President, Harrison Consulting Group, and Jordan Warshafsky, MBA, Partner, Ashton Tweed, Ltd.

BioPortUSA is a commercialization accelerator comprised of U.S.-based professional service firms with international reach that have partnered to aggregate all the service requirements of foreign-based life sciences firms entering the U.S. market. BioPortUSA is located at 620 Lee Road, Suite 130B, Wayne, PA 19087. For more information, please visit www.BioPortUSA.com